Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer
Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Maureen Trudeau(Trillium Health Centre), Laura B. Pritzker(Registered Nurses' Association of Ontario), Christine Solbach(Goethe University Frankfurt), Daniele Generali(University of Trieste), A. Hoenig, Paule Augereau(Institut de Cancérologie de l'Ouest), Ricardo Masetti(Agostino Gemelli University Polyclinic), Sara Rask(Royal Victoria Regional Health Centre), Nadia Califaretti(Grand River Hospital), Antonio Ardizzoia(Alessandro Manzoni Hospital), Amadeo M. Parissenti(Health Sciences North), Brigitte Poirier(Université Laval), Foluso O. Ademuyiwa(Washington University in St. Louis), Marie‐Ange Mouret‐Reynier(Centre Jean Perrin), Eva Ciruelos(Hospital Universitario 12 De Octubre), Lacey D. Pitre(Health Sciences North), Nicolás Isambert(Centre Georges François Leclerc), Dagmar Giesecke(Accadis Hochschule Bad Homburg), Sanaa Noubir(Registered Nurses' Association of Ontario), Thierry Petit, Manuela Milani(Humanitas University), B. Lex, Joke Tio(Ludwig-Maximilians-Universität München), Denise Wrobel(Olgahospital)
Cited by 3
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684